Clozapine safety, 35 years later

Current Drug Safety

Volumn 6, Issue 3, 2011, Pages 164-184

  Raja, Michele ^a  

^a Centro Studi e Ricerche Gaetano Perusini   (Italy)

Author keywords

Clozapine; Schizophrenia; Side effects; Treatment

Indexed keywords

AMANTADINE; AMISULPRIDE; AMITRIPTYLINE; BIPERIDEN; CHLORPROMAZINE; CHOLESTEROL; CLONIDINE; CLOZAPINE; GABAPENTIN; GHRELIN; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; INSULIN; LEPTIN; MEMANTINE; METFORMIN; MODAFINIL; NIZATIDINE; OLANZAPINE; PHENYLPROPANOLAMINE; PIRENZEPINE; REBOXETINE; RISPERIDONE; ROSIGLITAZONE; SCOPOLAMINE; SIBUTRAMINE; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE PANCREATITIS; AGGRESSION; AGRANULOCYTOSIS; BLOOD DYSCRASIA; CHOLESTEROL BLOOD LEVEL; COMPETENCE; CONSTIPATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DYSPNEA; ELECTROENCEPHALOGRAM; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; FEVER; FLU LIKE SYNDROME; FOCAL EPILEPSY; GENETICS; GRAND MAL SEIZURE; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ILEUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE PERFORATION; KIDNEY FAILURE; LEUKEMIA; MENTAL PATIENT; METABOLIC SYNDROME X; MYOCARDITIS; MYOCLONUS SEIZURE; NECROTIZING COLITIS; NEUTROPENIA; NOCTURNAL ENURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARKINSON DISEASE; PERITONITIS; PRIORITY JOURNAL; PSYCHOSIS; RASH; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; STOMACH OBSTRUCTION; SUICIDE; SWEATING; TACHYCARDIA; TARDIVE DYSKINESIA; THORAX PAIN; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; URINE INCONTINENCE; VIOLENCE; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; HUMANS; MOVEMENT DISORDERS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 80054115183     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611797579230     Document Type: Review

References (312)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for he treatment resistant schizophrenic. A double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45 (9): 789-96.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209-23.
3. Jones PB, Davies L, Barnes TR, et al. Randomized controlled trial of effect on quality of life of second-generation vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63(10): 1079-87.
4. Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. Curr Med Res Opin 1997; 14 (1): 1-20.
5. Meltzer HY, Bobo WV, Lee MA, et al. A randomized trial comparing clozapine and typical neuroleptic drugs in nontreatment- resistant schizophrenia. Psychiatr Res 2010; 177 (3): 286-93.
6. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk - benefit assessment. Am J Psychiatry 1995; 152(2): 183-90.
7. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576-80.
8. Duggan A, Warner J, Knapp M, et al. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 2003; 182: 505-8.
9. Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993; 13(4): 287-9.
10. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatr Law 1995; 23(4): 607-11.
11. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63 (6): 622-9.
12. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 2007; 164 (10): 1491-8.
13. Bassitt DP, Louza Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatr Clin Neurosci 1998; 248(4): 209-11.
14. Chang JS, Ha KS, Young Lee K, et al. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67(3): 461-7.
15. Fehr BS, Ozcan ME, Suppes T. Low doses of clozapine may stabilize treatment-resistant bipolar patients. Eur Arch Psychiatry Clin Neurosci 2005; 255(1): 10-4.
16. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64(4): 451-8.
17. Kant R, Chalansani R, Chengappa KN, et al. The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder. J Child Adolesc Psychopharmacol 2004; 14(1): 57-63.
18. Hayhurst KP, Brown P, Lewis SW. Postcode prescribing for schizophrenia. Br J Psychiatry 2003; 182: 281-3.
19. Griffith RW, Saameli K. Clozapine and agranulocytosis. Lancet 1975; 2(7936): 657.
20. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977; 11(3): 199-201.
21. Idänpään-Heikkilä J, Alhava E, Olkinuora M, et al. Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol 1977; 11 (3): 193-8.
22. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162-7.
23. Dev VJ, Rosenberg T, Krupp P. Agranulocytosis and clozapine. Br Med J 1994; 309(6946): 54.
24. Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother 1995; 6: 197-208.
25. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169(4): 483-8.
26. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47(1): 52-6.
27. Pirmohamed M, Park B. Mechanism of clozapine induced agranulocytosis. CNS Drugs 1997; 7: 139-58.
28. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47(10): 945-8.
29. Gerson LG, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994; 86(3): 555-61.
30. Uetrecht JP. Reactive metabolites and agranulocytosis. Eur J Haematol 1996; 57 (suppl.): 83-8.
31. Gerson SL. Clozapine - deciphering the risks. N Engl J Med 1993; 329(3): 204-5.
32. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55 Suppl B: 139-42.
33. Senechal A, Landry P, Deschamps R, et al. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002; 28(6 Pt 1): 567-9.
34. Patel NC, Dorson PG, Bettinger TL. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002; 36(6): 1012-5.
35. Small JG, Weber MC, Klapper MH, et al. Rechallenge of late-onset neutropenia with clozapine. J Clin Psychopharmacol 2005; 25(2): 185-6.
36. Kutscher EC, Robbins GP, Kennedy WK, et al. Clozapine-induced leukopenia successfully treated with lithium. Am J Health Syst Pharm 2007; 64(19): 2027-31.
37. Nongpiur A, Praharaj SK, Sarkar S, et al. Delayed Onset of Clozapine-Induced Leucopenia. Am J Ther. 2010; Aug 19 [Epub ahead of print].
38. Raja M, Azzoni A, Maisto G. Late onset neutropenia associated with clozapine. J Clin Psychopharmacol, in press.
39. Pascoe SJ. The adjunctive use of a centralized database in the monitoring of clozapine-related neutropenia. Pharmacoepidemiol Drug Saf 2003; 12(5): 395-8.
40. Safferman AZ, Lieberman JA, Alvir JM, et al. Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339(8804): 1296-7.
41. Barrons E, Johnson E, Nynkowski P. Restarting clozapine: a case report. Psychiatr Serv 1996; 47(1): 92.
42. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255-63.
43. Sperner-Unterweger B, Czeipek I, Gaggl S, et al. Treatment of severe clozapine-induced neutropenia with granulocyte colonystimulating factor (G-CSF)). Remission despite continuous treatment with clozapine. Br J Psychiatry 1998; 172: 82-4.
44. Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine- induced agranulocytosis. Int Clin Psychopharmacol 2003; 18(3): 173-4.
45. Majczenko T, Stewart J: Failure of filgrastim to prevent severe clozapine-induced agranulocytosis. South Med J 2008; 101(6): 639-40.
46. Joffe G, Eskelinen S, Sailas E. Add-On Filgrastim During Clozapine Rechallenge in Patients With a History of Clozapine- Related Granulocytopenia/Agranulocytosis. Am J Psychiatry 2009; 166(2): 236.
47. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006; 67(5): 756-60.
48. Blier P, Slater S, Measham T, et al. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 1998; 13(3): 137-40.
49. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003; 13(3): 401-4.
50. Papetti F, Darcourt G, Giordana JY, et al. Treatment of clozapineinduced granulocytopenia with lithium (two observations). Encephale 2004; 30(6): 78-82.
51. Adityanjee. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry 1995; 152(4): 648-9.
52. Bender S, Linka T, Wolstein J, et al. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int J Neuropsychopharmacol 2004; 7(1): 59-63.
53. Boshes RA, Manschreck TC, Desrosiers J, et al. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry 2001; 13(4): 233-7.
54. Mattai A, Fung L, Bakalar J, et al. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol 2009; 24(7): 584-9.
55. Kelly DL, Kreyenbuhl J, Dixon L, et al. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007; 33(5): 1221-4.
56. Madhusoodanan S, Cuni L, Brenner R, et al. Chronic leukocytosis associated with clozapine: a case series. J Clin Psychiatry 2007; 68(3): 484-8.
57. Sopko MA, Caley CF. Chronic leukocytosis associated with clozapine treatment. Clin Schizophr Relat Psychoses 2010; 4(2): 141-4.
58. Chatterton R. Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatry 1997; 31(6): 874-6.
59. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54(12): 466-9.
60. Ames D, Wirshing WC, Baker RW, et al. Predictive value of eosinophilia for neutropenia during clozapine treatment. J Clin Psychiatry 1996; 57(12): 579-81.
61. Young N. Agranulocytosis. JAMA 1994; 271(12): 935-8.
62. Chung SJ, Jeong SH, Ahn YM, et al. A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (1): 1 39-44.
63. Günther W, Baghai T, Naber D, et al. EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients. Pharmacopsychiatry 1993; 26 (3): 69-74.
64. Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997; 42 (2): 132-7.
65. Malow BA, Reese KB, Sato S, et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol 1994; 91 (3): 205-11.
66. Spatz R, Lorenzi E, Kugler J, et al. The incidence of abnormal EEG patterns with clozapine therapy. Arzneimittelforschung 1978; 28 (9): 1499-500.
67. Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. Am J Psychiatry 1978; 135(1): 99-100.
68. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41 (3): 369-71.
69. Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44 (12): 2247-9.
70. Devinsky O, Pacia SV: Seizures during clozapine therapy. J Clin Psychiatry 1994; 55(Suppl B): 153-6.
71. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6(3): 250-6.
72. Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007; 52 (7): 457-63.
73. Silvestri RC, Bromfield EB, Khoshbin S. Clozapine-induced seizures and EEG abnormalities in ambulatory psychiatric patients. Ann Pharmacother 1998; 32 (11): 1147-51.
74. Karper LP, Salloway SP, Seibyl JP, et al. Prolonged postictal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci 1992; 4 (4): 454-7.
75. Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010; 19 (2): 69-73.
76. Dumortier G, Lochu A, Colen de Melo P, et al: Elevated clozapine plasma concentrations after fluvoxamine. Am J Psychiatry 1996; 153(5): 738-9.
77. Funderburg L, Vertrees J, True J, et al: Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 1994; 151(12): 1840-1.
78. Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol 2003; 17(2): 234-8.
79. Langosch JM, Trimble MR. Epilepsy, psychosis and clozapine. Hum Psychopharmacol 2002; 17(2): 115-9.
80. Treves IA, Neufeld MY. EEG abnormalities in clozapine-treated schizophrenic patients. Eur Neuropsychopharmacol 1996; 6(2): 93-4.
81. Muzyk A, Gala G, Kahn DA. Use of lamotrigine in a patient with a clozapine-related seizure. J Psychiatr Pract 2010; 16(2): 125-8.
82. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994; 39(4): 236-8.
83. Prathama Guha, Haque S. Nizamie. Refractory schizophrenia, clozapine and epilepsy: management strategies. Indian J Psychiatry 1998; 40(1): 84-6.
84. Foster R, Olajide D. A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care. J Psychopharmacol 2005; 19(1): 93-6.
85. Usiskin SI, Nicolson R, Lenane M, et al. Gabapentin prophylaxis of clozapine-induced seizures (letter). Am J Psychiatry 2000; 157(3): 482-3.
86. Landry P. Gabapentin for Clozapine-Related Seizures Am J Psychiatry 2001; 158 (11): 1930-1.
87. Navarro V, Pons A, Romero A, et al. Topiramate for clozapineinduced seizures. Am J Psychiatry. 2001; 158(6): 968-9.
88. Chong SA, Remington G: Clozapine augmentation: safety and efficacy. Schizophr Bull 2000; 26(2): 421-40.
89. Weiser M, Knobler H, Lubin G, et al. Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry 2004; 65(11): 1546-9.
90. Kohen D: Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004; 47: S64-6.
91. Cohn TA, Wolever T, Bois D, et al. First episode and neuroleptic free patients with schizophrenia have reduced insulin sensitivity: a minimal model analysis. Schizophr Bull 2005; 31: 197-8.
92. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16(2): 77-89.
93. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(Suppl 7): 22-311
94. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16(2): 63-73.
95. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64(5): 575-9.
96. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83(1): 87-93.
97. Harris E, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53
98. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36(4): 239-45.
99. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70(1): 1-17 http://ajp.psychiatryonline.org/cgi/external_ref?access_num=15246458&link_type=MED.
100. Ghaeli P, Dufresne RL: Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53(17): 2079-81.
101. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(Suppl 18): 27-35.
102. Henderson DC, Daley TB, Kunkel L, et al. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65(5): 686-9.
103. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55 Suppl B: 157-60.
104. Bustillo JR, Buchanan RW, Irish D, et al. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996; 153(6): 817-9.
105. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149(5): 689-90.
106. Cohen S, Chiles J, MacNaughton A. Weight gain associated with clozapine. Am J Psychiatry 1990; 147(4): 503-4.
107. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment (letter). Am J Psychiatry 1994; 151(10): 1520-1.
108. Kostakoglu AE, Yazici KM, Erbas T, et al. Ketoacidosis as a sideeffect of clozapine: a case report. Acta Psychiatr Scand 1996; 93(3): 217-8.
109. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment (letter). Am J Psychiatry 1996; 153(5): 737-8.
110. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58(3): 108-11.
111. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44(8): 778-83.
112. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157(6): 975-81.
113. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159(4): 561-6.
114. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59(4): 337-45.
115. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60(6): 358-63.
116. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
117. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-- a systematic review. Acta Psychiatr Scand 2000; 101(6): 416-32.
118. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006; 29 (4): 303-19.
119. Rummel-Kluge C, Kommossa K, Schwartz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123 (2-3): 225-33.
120. Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine. Am J Psychiatry 2006; 163(7): 1273-6.
121. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186(4): 572-8.
122. Bai YM, Chen JY, Chen TT, et al. Weight gain with clozapine: 8- year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophr Res 2009; 108(1-3): 122-6.
123. Cerit C, Vural M, Bos Gelmez S.U{double acute}, et al. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull 2010; 43 (4): 22-36.
124. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010; 17(5): 460-6.
125. Hägg S, Lindblom Y, Myörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21(2): 93-8.
126. Bai YM, Lin CC, Chen JY, et al. Weight gain among patients on clozapine [letter]. Psychiatr Serv 1999; 50(5): 704-5.
127. De Leon J, Diaz FJ, Josiassen RC et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol 2007; 27(1): 22-7.
128. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010; 17(5): 460-6.
129. Hong CJ, Lin CH, Yu YW, et al. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001; 11(3): 265-8.
130. Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163(7): 1276-9.
131. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009; 43(6): 620-6.
132. Bai YM, Chen TT, Yang WS, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009; 111(1-3): 1-8.
133. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70(7): 1041-50.
134. Correll C, Penzner J, Parikh U, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006; 15(1): 177-206.
135. Brady K: Weight gain associated with psychotropic drugs. Southern Med J 1989; 82(5): 611-7.
136. Procyshyn RM, Wasan KM, Thornton AE, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatr Neurosci 2007; 32(5): 331-8.
137. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149(1): 68-72.
138. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002; 22(3): 244-51.
139. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003; 59(1): 19-27.
140. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry 2005; 44(9): 925-33.
141. Bobo WV, Jayathilake K, Lee MA, et al. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. Psychiatry Res 2010; 176(2-3): 114-9.
142. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5(4): 437-40.
143. Kivircik BB, Alptekin K, Calişkan S, et al. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(5): 795-9.
144. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70(1): 19-26.
145. Caballero E. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr 2003; 8(11 Suppl 2): 19-22.
146. Prior T, Chue P, Tibbo P: Oral glucose challenge test abnormalities with atypical antipsychotic use. Schizophr Res 1999; 36: 357-8.
147. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine (letter). Am J Psychiatry 1994; 151(9): 1395.
148. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157(6): 975-81.
149. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002; 14(1): 59-64.
150. Remington G. Schizophrenia, Antipsychotics, and the Metabolic Syndrome: Is There a Silver Lining? Am J Psychiatry 2006; 163(7): 1132-4.
151. Bai YM, Lin CC, Chen JY, et al. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry 2010; Nov 30. [Epub ahead of print].
152. Melkersson U, Hulting A, Bismar K. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60(11): 783-91.
153. Wetterling T, Mubigbrodt H: Weight gain: side effect of atypical neuroleptics. J Clin Psychopharmacol 1999; 19(4): 316-21.
154. Melkersson K, Jansson E. Effects of the atypical antipsychotic clozapine on insulin release in vitro. Neuro Endocrinol Lett 2007; 28(6): 854-60.
155. Howes OD, Bhatnagar A, Gaughran FP, et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004; 161(2): 361-3.
156. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006; 20(1): 75-9.
157. Theisen FM, Gebhardt S, Brömel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005; 112(10): 1411-6.
158. Sentissi O, Epelbaum J, Olié JP, et al. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008; 34(6): 1189-99.
159. Himmerich H, Fulda S, Künzel HE, et al. Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005; 52(1): 11-6.
160. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64(5): 598-604.
161. Esen-Danaci A, Sarandöl A, Taneli F, et al. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1434-8.
162. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 2002; 47(8): 742-9.
163. Monteleone P, Fabrazzo M, Tortorella A, et al. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment. J Clin Psychopharmacol 2002; 22(4): 424-6.
164. Palik E, Birkás KD, Faludi G, et al. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005; 68(Suppl 1): S60-4.
165. Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002; 22(15): 6742-6.
166. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry 2007; 68(12): 1834-9.
167. Hanssens L, van Winkel R, Wampers M, et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008; 106(2-3): 308-14.
168. Theisen FM, Cichon S, Linden A, et al. Clozapine and weight gain. Am J Psychiatry 2001; 158(5): 816.
169. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005; 15(4): 285-9.
170. Gebhardt S, Theisen FM, Haberhausen M, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 2010; 35(2): 207-11.
171. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359(9323): 2086-7.
172. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15(4): 195-200.
173. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005; 134B(1): 76-8.
174. Miller DD, Ellingrod VL, Holman TL, et al. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 133B(1): 97-100.
175. Reynolds GP, Zhang ZJ, Zhang XB: Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160(4): 677-9.
176. Tsai SJ, Hong CJ, Yu YW, et al. -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain (letter). Lancet 2002; 360(9347): 1790.
177. Rietschel M, Naber D, Fimmers R, et al. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997; 8(8): 1999-2003.
178. Theisen FM, Hinney A, Brömel T, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004; 14(3): 139-42.
179. Yevtushenko OO, Cooper SJ, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008; 192(6): 424-8.
180. Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009; 29(1): 65-8.
181. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. J Psychopharmacol 2006; 20(4 Suppl): 15-8.
182. Finn PD, Cunningham MJ, Rickard DG, et al. Serotonergic neurons are targets for leptin in the monkey. J Clin Endocrinol Metab 2001; 86(1): 422-6.
183. Hay-Schmidt A, Helboe L, Larsen PJ. Leptin receptor immunoreactivity is present in ascending serotonergic and catecholaminergic neurons of the rat. Neuroendocrinology 2001; 73(4): 215-26.
184. De Luca V, Müller DJ, Hwang R, et al. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum Psychopharmacol 2007; 22(7): 463-7.
185. Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27(4): 338-43.
186. Bai YM, Chen TT, Liou YJ, et al. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res 2011; 125(2-3): 179-86.
187. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009; 29(1): 16-20.
188. Tiwari AK, Rodgers JB, Sicard M, et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(8): 1484-90.
189. Hong CJ, Lin CH, Yu YW, et al. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet 2002; 12(3): 169-71.
190. Liou YJ, Bai YM, Lin E, et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics 2010; Sep 28. [Epub ahead of print].
191. Monteleone P, Milano W, Petrella C, et al. Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. J Clin Psychopharmacol 2010; 30(4): 441-5.
192. Tiwari AK, Rodgers JB, Sicard M, et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(8): 1484-90.
193. Sickert L, Müller DJ, Tiwari AK, et al. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychoticinduced weight gain in European-Americans. Pharmacogenomics 2009; 10(7): 1169-76.
194. Wang YC, Bai YM, Chen JY, et al. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005; 112(11): 1463-8.
195. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62 Suppl 23: 45-66.
196. Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under longterm atypical antipsychotic treatment. Pharmacogenet Genomics 2010; 20(6): 359-66.
197. Le Hellard S, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry 2009; 14(3): 308-17.
198. Wang YC, Bai YM, Chen JY, et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005; 15(10): 743-8.
199. Tsai SJ, Yu YW, Lin CH, et al. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004; 50(1): 37-40.
200. Carrizo E, Fernández V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009; 113(1): 19-26.
201. Ehret M, Goethe J, Lanosa M, et al. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 2010; 71(10): 1286-92.
202. Schaefer M, Leopold K, Hinzpeter A, et al. Memantine-associated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007; 40(4): 149-51.
203. Borovicka MC, Fuller MA, Konicki PE, et al. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 2002; 63(4): 345-8.
204. Henderson DC, Fan X, Sharma B, et al. A double-blind, placebocontrolled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 2009; 119(6): 457-65.
205. Henderson DC, Louie PM, Koul P, et al. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 2005; 17(2): 95-7.
206. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66(9): 1116-21.
207. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25(1): 32-41.
208. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8(6): 671-7.
209. Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60(1): 82-91.
210. Greenberger NJ, Toskes PT. Acute and chronic pancreatitis. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser LH, Jameson JL, Loscalzo J, Eds. Harrison's Principles of Internal Medicine, 17th ed. Mc Graw Hill, Medical, New York, 2008, pp. 2005-17.
211. Wilmink T, Frick TW. Drug-induced pancreatitis. Drug Saf 1996; 14(6): 406-23.
212. Koller EA, Cross JT, Doraswamy PM et al. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23(9): 1123-30.
213. Sani G, Kotzalidis GD, Simonetti A, et al. Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. J Clin Psychopharmacol 2010; 30(6): 737-9.
214. Raja M, Azzoni A. Clozapine-induced pancreatitis. Open Neuropsychopharmacol J, 2011, 4, 5-7 5. 1876-5238/.
215. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990; 40(5): 722-47.
216. Liebermann JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151(12): 1744-52.
217. Hayes G, Gibler B. Clozapine-induced constipation. Am J Psychiatry 1995; 152(2): 298.
218. Flanagan RJ, Ball RY. Gastrointestinal hypomotility: An underrecognised life-threatening adverse effect of clozapine. Forensic Sci Int 2011; 206(1-3): e31-6.
219. Schwartz BJ, Frisolone JA. A case report of clozapine-induced gastric outlet obstruction. Am J Psychiatry 1993; 150(10): 1563.
220. Erickson B, Morris DM, Reeve A. Clozapine-associated postoperative ileus: case report and review of the literature. Arch Gen Psychiatry 1995; 52(6): 508-9.
221. Théret L, Germain ML, Burde A. Current aspects of the use of clozapine in the Châlons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine. Ann Med Psychol (Paris) 1995; 153(7): 474-7.
222. Drew L. Herdson P. Clozapine and constipation: a serious issue. Aust N Z J Psychiatry 1997; 31(1): 149-50.
223. Shammi CM, Remington G. Clozapine induced necrotizing colitis. J Clin Psychopharmacol 1997; 17(3): 230-2.
224. Tang WK, Ungvari GS. Clozapine-induced intestinal obstruction. Aust N Z J Med 1999; 29(4): 560.
225. Freudenreich O, Goff DC. Colon perforation and peritonitis associated with clozapine. J Clin Psychiatry 2000; 61(12): 950-1.
226. Levin TT, Barrett J, Mendelowitz A. Death from clozapine-induced constipation: case report and literature review. Psychosomatics 2002; 43(1): 71-3.
227. Karmacharya R, Mino M, Pirl WF. Clozapine-induced eosinophilic colitis. Am J Psychiatry 2005; 162(7): 1386-7.
228. Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry 2006; 6: 43.
229. Rousseau A, Charbonneau M: Severe fecal impaction under clozapine, resulting in death. J AMPQ (Assoc des Médécins Psychiatres du Québec) 2007; 11: 16-8.
230. Pegah P, Bourgeois J. Clozapine, fluoxetine, and benztropine associated ileus: case report. Jefferson J Psychiatry 2007; 21 (1).
231. Rondla S, Crane S. A case of clozapine-induced paralytic ileus. Emerg Med J 2007; 24(2): e12.
232. Hibbard KR, Propst A, Frank DE, et al. Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports. Psychosomatics 2009; 50(4): 416-9.
233. Liaw CC, Wang CH, Chang HK, et al. Control of cisplatin-induced emesis with intravenous ondansetron plus intravenous dexamethasone: a crossover study of triple 8-mg dose of ondansetron. Am J Clin Oncol 2000; 23(3): 253-7.
234. McKinnon ND, Azad A, Waters BM, et al. Clozapine-induced Bowel Infarction: A Case Report. Psychiatry (Edgmont) 2009; 6(3): 30-5.
235. Leong QM, Wong KS, Koh DC. Necrotising colitis related to clozapine? A rare but life threatening side effect. World J Emerg Surg 2007; 2: 21.
236. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Lifethreatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69(5): 759-68.
237. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354(9193): 1841-5.
238. Committee on Safety of Medicines: Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Prob Pharmacovigilance 1993; 19: 9.
239. Degner D, Bleich S, Grohmann R, et al. Myocarditis associated with clozapine treatment. Aust NZ J Psychiatry 2000; 34(5): 880.
240. La Grenade L, Graham D, Trontell A: Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345(3): 224-5.
241. Hagg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21(4): 382-8.
242. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322(7296): 1207-9.
243. Dukes MN: The importance of adverse reactions in drug regulation. Drug Saf 1990; 5(1): 3-6.
244. Wehmeier PM, Schuler-Springorum M, Heiser P, et al. Chart review for the potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. J Child Adolesc Psychopharmacol 2004; 14(2): 267-71.
245. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust NZ J Psychiatry 2004; 38(11-12): 915-22.
246. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30(1): 47-57.
247. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343(19): 1388-98.
248. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009; 190(4): 190-2.
249. Ariyarajah V, Shaikh N, Garber PJ, et al. Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J Magn Reson Imaging 2010; 31(6): 1473-6.
250. Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 2008; 121(1283): 68-75.
251. Ronaldson KJ, Taylor AJ, Fitgerald PB, et al. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010; 71(8): 976-81.
252. Tham JC, Dickson RA. Clozapine-induced fevers and 1-year clozapine disco6ntinuation rate. J Clin Psychiatry 2002; 63(10): 880-4.
253. Fineschi V, Neri M, Riezzo I, et al. Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. Int J Legal Med 2004; 2004; 118(5): 307-9.
254. Pollmacher T, Schuld A, Kraus T, et al. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokinereceptors. Fortschr Neurol Psychiatr 2001; 69(Suppl 2): S65-74.
255. Burian J, Buser P, Eriksson U: Myocarditis: the immunologist's view on pathogenesis and treatment. Swiss Med Wkly 2005; 135(25-26): 359-64.
256. Breier A, Buchanan RW, Waltrip RW II, et al. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 1994; 10(1): 1-7.
257. Wang JF, Min JY, Hampton TG, et al. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol Eur J Pharmacol 2008; 592(1-3): 123-7.
258. Wang JF, Zhang J, Min JY, et al. Cocaine enhances myocarditis induced by encephalomyocarditis virus in murine model. Am J Physiol Heart Circ Physiol 2002; 282(3): H956-63.
259. Williams DP, O'Donnell CJ, Maggs JL, et al. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem Res Toxicol 2003; 16(10): 1359-64.
260. Macfarlane B, Davies S, Mannan K, et al. Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112(5): 1707-9.
261. Kellner M, Wiedemann K, Krieg JC, et al. Toxic hepatitis by clozapine treatment. Am J Psychiatry 1993; 150(6): 985-6.
262. Hovens JE, Vogtländer LM, Verhoeve HA, et al. Liver cell necrosis during administration of clozapine. Ned Tijdschr Geneeskd 1994; 138(7): 363-5.
263. Thatcher GW, Cates M, Bair B. Clozapine-induced toxic hepatitis. Am J Psychiatry 1995; 152(2): 296-7.
264. Worrall R, Wilson A, Cullen M. Dystonia and drug-induced hepatitis in a patient treated with clozapine. Am J Psychiatry 1995; 152(4): 647-8.
265. Wirshing WC, Ames D, Bisheff S, et al. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 1997; 17(2): 120-1.
266. Thompson J, Chengappa KN, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13(2): 95-8.
267. Luo D, McColl P, Walmsley R. Acute onset of ascites with clozapine-induced hepatitis. Internal Med J 2007; 37(3): 204-5.
268. Chang, A, Krygier DS, Chatur N, et al. Clozapine-induced fatal fulminant hepatic failure: A case report. Can J Gastroenterol 2009; 23(5): 376-8.
269. Gómez Espín R, Sánchez Quiles I, Hallal H, et al. Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection. Gastroenterol Hepatol 2010; 33(2): 150-2.
270. Hummer M, Jurz M, Jurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychpharmacol 1997; 17(4): 314-7.
271. Gaertner I, Altendorf K, Batra A, et al. Relevance of liver enzyme elevations with four different neuroleptics: A retrospective review of 7263 treatment courses. J Clin Psychpharmacol 2001; 21(2): 215-22.
272. Elias TJ, Bannister KM, Clarkson AR, et al. Clozapine-induced acute interstitial nephritis. Lancet 1999; 354(9185): 1180-1.
273. Fraser D, Jibani M. An unexpected and serious complication of treatment with the atypical antipsychotic drug clozapine. Clin Nephrol 2000; 54(1): 78-80.
274. Southall K, Fernando N. A case of interstitial nephritis on clozapine. Aust N Z J Psychiatry 2000; 34: 697-8.
275. Estébanez C, Fernández Reyes MJ, Sánchez Hernández R, et al. Nefritis interstitial aguda inducida por clozapina. Nefrología 2002; 22(3): 277-81.
276. Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. Am J Psychiatry 2004; 161(8): 1501.
277. Hunter R, Gaughan T, Queirazza F, et al. Clozapine-induced interstitial nephritis - a rare but important complication: a case report. J Med Case Rep 2009; 3: 8574.
278. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: Pathophysiology and management strategies. Psychopharmacology 2006; 185(3): 265-73.
279. Syed R, Au K, Cahill C, et al. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev 2008; (3): CD005579.
280. Lieberman JA: Maximizing clozapine treatment: managing side effects. J Clin Psychiatry 1998; 59(Suppl 3): 38-43.
281. Miller DD: Review and management of clozapine side effects. J Clin Psychiatry 2000; 61 (suppl 8): 14-7.
282. Young CR, Bowers MB, Mazure CM: Management of the adverse effects of clozapine. Schizophr Bull 1998; 24(3): 381-90.
283. Naber D: Optimizing clozapine treatment. J Clin Psychiatry 1999; 60 (suppl 12): 35-8.
284. Praharaj SK, Verma P, Roy D, et al. Is clonidine useful for treatment of clozapine-induced sialorrhea? J Psychopharmacol 2005; 19(4): 426-8.
285. Ekström J, Godoy T, Riva A. Clozapine: agonistic and antagonistic salivary secretory actions. J Dent Res 2010; 89(3): 276-80.
286. Praharaj SK, Jana AK, Goswami K, et al. Salivary flow rate in patients with schizophrenia on clozapine. Clin Neuropharmacol 2010; 33(4): 176-8.
287. Antonello C, Tessier P: Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. J Psychiatry Neurosci 1999; 24(3): 250.
288. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapineinduced sialorrhea. Br J Psychiatry 1991; 159: 166.
289. Schneider B, Weigmann H, Hiemke C, et al. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004; 37(2): 43-5.
290. Robb AS, Lee RH, Cooper EB, et al. Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents. J Child Adolesc Psychopharmacol 2008; 18(1): 99-107.
291. Poyurovski M, Modai I, Weizman A. Trihexyphenidyl as a possible therapeutic option in clozapine induced nocturnal enuresis. Int Clin Psychopharmacol 1996; 11: 61-3.
292. Spivak B, Adlersberg S, Rosen L, et al. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 1997; 12(4): 213-5.
293. Aggarwal A, Garg A, Jiloha RC. Trihexyphenidyl (benzhexol) in clozapine-induced nocturnal enuresis and sialorrhea. Indian J Med Sci 2009; 63(10): 470-1.
294. Praharaj SK, Sarkhel S, Khanande RV, et al. Complete resolution of clozapine-induced sialorrhea with low dose trihexyphenidyl. Psychopharmacol Bull 2010; 43 (4): 73-5.
295. Croissant B, Hermann D, Olbrich R. Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation-a case report. Pharmacopsychiatry 2005; 38(1): 38-9.
296. Aggarwal A, Sharma DD. Amisulpride for clozapine induced sialorrhea. Psychopharmacol Bull 2009; 42 (4): 69-71.
297. Gaftanyuk O, Trestman RL. Scolpolamine patch for clozapineinduced sialorrhea. Psychiatr Serv 2004; 55(3): 318.
298. Kahl KG, Hagenah J, Zapf S, et al. Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology (Berl) 2004; 173(1-2): 229-30.
299. Freudenreich O, Beebe M, Goff DC. Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series. J Clin Psychopharmacol 2004; 24(1): 98-100.
300. Calderon J, Rubin E, Sobota WL. Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 2000; 15(1): 49-52.
301. Kreinin A, Epshtein S, Sheinkman A, et al. Sulpiride addition for the treatment of clozapine-induced hypersalivation: preliminary study. Isr J Psychiatry Relat Sci 2005; 42(1): 61-3.
302. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006; 21(2): 99-103.
303. Wang J, Omori IM, Fenton M, et al. Sulpiride augmentation for schizophrenia Cochrane Database Syst Rev 2010; (1): CD008125.
304. Steinlechner S, Klein C, Moser A, et al. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology (Berl) 2010; 207(4): 593-7.
305. Sockalingam S, Shammi C, Remington G. Treatment of clozapineinduced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2009; 70(8): 1114-9.
306. Bai YM, Lin CC, Chen JY, et al. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 2001; 21(6): 608-11.
307. Lowe CM, Grube RR, Scates AC. Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 2007; 41(10): 1700-4.
308. Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16 (5): 403-9.
309. Kho KH, Nielsen O. Clozapine-induced nocturnal enuresis. Psychiatr Bull R Coll Psychiatr 2001; 25: 232-3.
310. Lin CC, Bai YM, Chen JY, et al. A retrospective study of clozapine and urinary incontinence in Chinese in-patients. Acta Psychiatr Scand 1999; 100(2): 158-61.
311. Steingard S. Use of desmopressin to treat clozapine-induced nocturnal enuresis. J Clin Psychiatry 1994; 55(7): 315-6.
312. Glazener CM, Evans JH, Peto RE. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev 2003; 3: CD002117.